Sanofi (SAN1N.MX)
| Previous close | 1,629.20 |
| Open | 0.00 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 1,629.20 - 1,629.20 |
| 52-week range | 1,609.59 - 1,978.38 |
| Volume | |
| Avg. volume | 722 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | 14.47 |
| EPS (TTM) | 112.62 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Yahoo Finance UKTrending tickers: TSMC, Novavax, Anglo American and IAG
The latest investor updates on stocks that are trending on Friday
Globe NewswirePress Release: Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines
Sanofi and Novavax announce co-exclusive licensing agreement to co-commercialize COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines Agreement provides patients with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwards Accelerates potential for development of a novel flu-COVID-19 combination product based on authorized vaccines with demonstrated efficacy and tolerability, potentially offering patients enha
PR NewswireNovavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, has entered into a co-exclusive licensing agreement with Sanofi (Nasdaq: SNY).
